Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
Importance A critical decision in the management of metastatic castration-resistant prostate
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a
taxane. Objective To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-
V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-
specific marker for response and outcomes between ARS inhibitors and taxanes. Design,
Setting, and Participants For this cross-sectional cohort study at Memorial Sloan Kettering …
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a
taxane. Objective To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-
V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-
specific marker for response and outcomes between ARS inhibitors and taxanes. Design,
Setting, and Participants For this cross-sectional cohort study at Memorial Sloan Kettering …
